Following the Thread of Cancer and Genetics

People who undergo genetic testing for potentially inherited cancers generally do so to be better prepared to understand and deal with their personal cancer risk. This information, however, can also be shared to help cancer researchers in their important work. PROMPT (Prospective Registry of Multi-Plex Testing) is a new online registry in which individuals can share their results from tests for inherited cancer-causing genetic mutations.

The PROMPT registry was co-founded by multiple experts from academic medical centers as well as genetic laboratories, including the Dana-Farber Cancer Institute, Mayo Clinic, Memorial Sloan Kettering Cancer Center (MSK), and Penn Medicine. An online patient portal opened to patients this past summer, allowing individuals to share data that could improve the understanding of genetic cancer links.

The information gathered from this portal is expected to be particularly useful when it comes to improved understanding the panel testing of multiple cancer genes. These new tests include numerous cancer genes which have only recently been discovered. By tracking more patients, experts hope to develop a better understanding of preventive strategies with these cancers.

This registry offers several levels of participation. Patients can anonymously share their test results and leave it at that. Or they can be more involved, such as by providing access to more clinical details about themselves, outcomes assessment, and information about individual gene variants in their families. Patients can even be involved in studies that will be run through PROMPT. More information about the PROMPT registry can be found at

Stephen C. Vogt, Pharm.D.
President and CEO
BioPlus Specialty Pharmacy


What do you think?

I’d love to hear your opinion in the comments section below.



Press release. New academic-industry partnership creates online registry for patients tested for inherited cancer risk. Memorial Sloan Kettering Cancer Center. September 23, 2014.

Leave a Reply